Bushen Yijing Fang Reduces Fall Risk in Late Postmenopausal Women with Osteopenia: A Randomized Double-blind and Placebo-controlled Trial

Yuxin Zheng, Xuezong Wang, Zongkang Zhang, Baosheng Guo, Lei Dang, Bing He, Chi Zhang, Jiwei Zhou, Wanzhong Shi, Yongfang Zhao, Hongsheng Zhan, Yu Xu, Chao Liang, Jin Liu, Daogang Guan, Luyao Wang, Xiaohao Wu, Jie Li, Zhenjian Zhuo, Zhi‐Xiu Lin, Hong Qiu, Linda L. D. Zhong, Zhaoxiang Bian, Yin-Yu Shi, Bao‐Ting Zhang, Ge Zhang, Aiping LüScientific 2019 · DOI

Abstract

Falls in late postmenopausal women with osteopenia usually cause fractures with severe consequences. This 36-month randomized, double-blind and placebo-controlled trial with a 10-year observational follow-up study aimed to investigate the long-term effect of herbal formula Bushen Yijing Fang (BSYJF) on fall risk in the late postmenopausal women with osteopenia. 140 late postmenopausal women (Femoral neck T-score, -2.5~-2 SD) were recruited and randomized to orally receive calcium carbonate 300 mg daily with either BSYJF or placebo for 36 months. The effect was further investigated for another 10-year follow-up. During the 36-month administration, there were 12 falls in BSYJF group and 28 falls in placebo group, respectively, indicating 64% lower risk of falls (RR 0.36 [95% CI, 0.18 to 0.71]; P = 0.004) in BSYJF group. During the 10-year follow-up, 36% lower fall risk (RR 0.64 [95% CI, 0.46 to 0.89]; P = 0.009) was observed in BSYJF group. No significant difference was found in safety profile between two groups. Thirty-six-month administration of BSYJF reduced fall risk with an increase in bone mass, and its latent effect on fall risk was continually observed in the 10-year follow-up in late postmenopausal women with osteopenia.

Introduction

Falls represent a major public health challenge for late postmenopausal women, often leading to debilitating fractures and increased mortality. While clinical focus is frequently directed toward osteoporosis, a significant proportion of fractures occur in women with osteopenia—a state of moderate bone loss. Fall risk in this population is multifactorial, driven by both skeletal integrity (bone-dependent) and neuromuscular stability (bone-independent). Current interventions, such as Vitamin D supplementation, have yielded inconsistent results in fall prevention. This study evaluates the efficacy of Bushen Yijing Fang (BSYJF), a Traditional Chinese Medicine (TCM) herbal formula, in addressing both bone density and physical stability to reduce long-term fall risk.

Methods

This study utilized a gold-standard randomized, double-blind, placebo-controlled design. Researchers recruited 140 community-dwelling women (aged 55–69) in Shanghai with osteopenia (femoral neck T-score between -2.5 and -2.0). Participants were randomized to receive either 300mg of calcium daily with BSYJF capsules or a placebo for 36 months. Following the active treatment phase, a 10-year observational follow-up was conducted to assess the longevity of the treatment's effects.

Study flow diagram illustrating the recruitment, randomization, and follow-up phases of the 36-month trial and 10-year observational study.

Primary outcomes included the number of falls, while secondary metrics encompassed functional mobility (Timed Up and Go [TUG] test), lean thigh muscle mass, and Bone Mineral Density (BMD). Bioinformatics network analysis was also employed to map the seven herbs in BSYJF to target genes involved in muscle regulation and bone metabolism.

Results

Primary Endpoint: Fall Risk Reduction

During the 36-month intervention, the BSYJF group demonstrated a 64% lower risk of falls compared to the placebo group (RR 0.36, p=0.004). Remarkably, this benefit persisted long after treatment cessation; the BSYJF group maintained a 36% lower fall risk (RR 0.64, p=0.009) throughout the 10-year observational follow-up, suggesting a significant "legacy effect."

Dual-Action Mechanism: Bone and Muscle

The efficacy of BSYJF is attributed to its simultaneous impact on skeletal and neuromuscular health. While the formula significantly increased BMD (+3.86% vs. -4.05% in placebo), its prevention of falls was strongly linked to the maintenance of lean muscle mass and functional mobility. As shown in the clinical data, the placebo group experienced significant declines in thigh muscle mass and TUG performance, whereas the BSYJF group remained stable.

Impact of BSYJF on fall incidence, cumulative incidence of first fall, lean thigh mass, and Timed Up and Go (TUG) performance over 36 months.

Safety and Synergetic Action

Bioinformatics revealed that the formula's success relies on synergistic action: specific herbs target muscle strength while others support bone integrity. Safety profiles were excellent, with no significant differences in adverse events between groups and no estrogen-like effects on endometrial thickness, indicating BSYJF provides phytoestrogenic benefits without associated hormonal risks.

Discussion and Conclusion

The findings suggest that BSYJF offers a comprehensive approach to geriatric care by addressing the dual drivers of fall risk. The observed "legacy effect" indicates that a 36-month course of BSYJF may provide decade-long protection against falls in postmenopausal women with osteopenia. While limitations include the inherent complexity of fall-related lifestyle factors and the need for larger samples to confirm hip fracture reduction, BSYJF represents a promising therapeutic agent for enhancing long-term musculoskeletal health and stability.

Summary updated

Abstract

Falls in late postmenopausal women with osteopenia usually cause fractures with severe consequences. This 36-month randomized, double-blind and placebo-controlled trial with a 10-year observational follow-up study aimed to investigate the long-term effect of herbal formula Bushen Yijing Fang (BSYJF) on fall risk in the late postmenopausal women with osteopenia. 140 late postmenopausal women (Femoral neck T-score, -2.5~-2 SD) were recruited and randomized to orally receive calcium carbonate 300 mg daily with either BSYJF or placebo for 36 months. The effect was further investigated for another 10-year follow-up. During the 36-month administration, there were 12 falls in BSYJF group and 28 falls in placebo group, respectively, indicating 64% lower risk of falls (RR 0.36 [95% CI, 0.18 to 0.71]; P = 0.004) in BSYJF group. During the 10-year follow-up, 36% lower fall risk (RR 0.64 [95% CI, 0.46 to 0.89]; P = 0.009) was observed in BSYJF group. No significant difference was found in safety profile between two groups. Thirty-six-month administration of BSYJF reduced fall risk with an increase in bone mass, and its latent effect on fall risk was continually observed in the 10-year follow-up in late postmenopausal women with osteopenia. This clinical trial was registered at Chinese clinical trial registry (ChiCTR-IOR-16008942).
BibTeX
@inproceedings{zheng2019bushen,
  author = {Yuxin Zheng and Xuezong Wang and Zongkang Zhang and Baosheng Guo and Lei Dang and Bing He and Chi Zhang and Jiwei Zhou and Wanzhong Shi and Yongfang Zhao and Hongsheng Zhan and Yu Xu and Chao Liang and Jin Liu and Daogang Guan and Luyao Wang and Xiaohao Wu and Jie Li and Zhenjian Zhuo and Zhi‐Xiu Lin and Hong Qiu and Linda L. D. Zhong and Zhaoxiang Bian and Yin-Yu Shi and Bao‐Ting Zhang and Ge Zhang and Aiping Lü},
  title = {{Bushen Yijing Fang Reduces Fall Risk in Late Postmenopausal Women with Osteopenia: A Randomized Double-blind and Placebo-controlled Trial}},
  booktitle = {Scientific},
  year = {2019},
  doi = {10.1038/s41598-018-38335-3},
}
Figure